Learn / Clinical Research Management / Safety in clinical trials
Pharmacovigilance and risk management
12 minute read · 6-question quiz
What you will learn
Explain pharmacovigilance and how it continues after approval
Describe spontaneous reporting and signal detection
Outline risk management plans and how trial safety links to post-marketing safety
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. It covers the whole life of a medicine, from the early clinical trials through years of marketed use.
Why PV continues after approval
Trials involve a limited number of carefully selected people for a limited time. They cannot find rare effects (for example, 1 in 10,000), delayed effects, or effects in groups excluded from trials, such as pregnant women, older people, or those with other conditions. Post-marketing PV fills these gaps.
Sources of safety information
- Clinical trials, including long-term extensions.
- Spontaneous reports from health professionals, patients and companies.
- Registries and electronic health records.
- Published literature.
- Regulatory databases such as national pharmacovigilance centres, which in many countries link to the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre).
Signal detection
Analysts review reports for patterns that are more frequent than expected, using clinical review and statistical tools to compare observed and expected reporting. A signal is hypothesis-generating: it requires evaluation, such as a study, before concluding the drug causes harm.
Risk management
A risk management plan (RMP) describes known and potential safety concerns, plans to study them further (pharmacovigilance activities), and risk minimisation measures such as restricted prescribing, special labelling, educational materials or required laboratory monitoring.
Why trial staff should care about PV
- High-quality AE data from trials feed the safety database used throughout the product's life.
- Accurate MedDRA coding allows events to be compared across studies.
- Trial teams are often the first to see safety patterns.
- Reporting suspected reactions also matters once a medicine is in routine use: in many countries, health workers can report to the national pharmacovigilance centre.
Summary
Pharmacovigilance covers detection, assessment, understanding and prevention of drug-related problems throughout a product's life.
Trials miss rare, delayed and special-population effects; post-marketing surveillance fills the gap.
Signals are hypotheses that require evaluation before conclusions are drawn.
Risk management plans set out how known and potential risks are monitored and minimised.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.